Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T) therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022. As a result, the Company’s total number of voting rights is now 24,962,331.

Tue, 31 May 2022 01:42 PM (IST)
 0
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, May 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and the development of Chimeric Antigen Receptor T cell (CAR T) therapies for cancer, announced that 350 registered shares benefit from a double voting right as of May 25, 2022. As a result, the Company’s total number of voting rights is now 24,962,331.

Sangri Today Sangri Today is a Weekly Bilingual Newspaper and website of news and current affairs that publishes news reports from various places, from general reports.